Entweder 10000% oder Totalverlust
19.09.02 17:09
#77
grenke
bin auch am überlegen alle Nemax-positionen glatt
zu stellen, und alles auf caly.
denke hier ist eine megachance die wir so schnell nicht wiedersehen.
gruß Grenke
P.S Kostelany hätte spass an solchen papieren( Aktien kaufen die fast nichts mehr wert sind)
denke hier ist eine megachance die wir so schnell nicht wiedersehen.
gruß Grenke
P.S Kostelany hätte spass an solchen papieren( Aktien kaufen die fast nichts mehr wert sind)
19.09.02 17:09
#78
Stox Dude
die ersten 30,000 confirmed
Buy 30,000 Limit 0.118 Day Only 11:00 am 09/19/2002 ET ----- -----
Bought 30,000 0.118 11:01 am 09/19/2002 ----- -----
Bought 30,000 0.118 11:01 am 09/19/2002 ----- -----
19.09.02 17:13
#81
Stox Dude
ich werde wahnsinnig, nur ein kl. Teilkauf
Buy 80,000 Limit 0.118 Day Only 11:07 am 09/19/2002 ET Change Cancel
Bought
Partial Fill 5,000 0.118 11:11 am 09/19/2002 ----- -----
Bought
Partial Fill 5,000 0.118 11:11 am 09/19/2002 ----- -----
Bought
Partial Fill 5,000 0.118 11:11 am 09/19/2002 ----- -----
Bought
Partial Fill 5,000 0.118 11:11 am 09/19/2002 ----- -----
19.09.02 17:13
#83
grenke
in Berlin wollen die jetzt 0,13 haben
Puh ich denke mit 0,14 liege ich genau richtig.
wären immer noch fast 20% im Daydrading bei Ankauf in Frankfurth zu 0,12
wären immer noch fast 20% im Daydrading bei Ankauf in Frankfurth zu 0,12
19.09.02 17:14
#85
Stox Dude
bought = gekauft, weitere 10k shares
jetzt fehlen noch 60,000
Volumen ueber 3 Mio shares in USA
Volumen ueber 3 Mio shares in USA
19.09.02 17:16
#86
sbroker
ja klar, stox will aber 80.000 stk und kriegt sie
in 5000 er paketen, würde mich auch nerven!
19.09.02 17:17
#88
Stox Dude
mit dem FDA approval geht das Ding
mind. 0,50
lassen wir mal unsere Fantasie spielen, was ist wenn Caly am
Nasi gelistet wird und wir sind alle noch shareholder ?
lassen wir mal unsere Fantasie spielen, was ist wenn Caly am
Nasi gelistet wird und wir sind alle noch shareholder ?
19.09.02 17:18
#91
auf geht´s
was man heute günstig erhaschen kann sollte man
auch tun, wenn sich das in Ami-Land rumspricht geht´s ne Woche lang jeden Tag 30-50% hoch.
Das letzte High bei rund 0,35 $ sollte eigentlich kein Problem sein - danach geht´s nur noch weiter ohne Grenzen!
AUF GEHT`S
Das letzte High bei rund 0,35 $ sollte eigentlich kein Problem sein - danach geht´s nur noch weiter ohne Grenzen!
AUF GEHT`S
19.09.02 17:18
#92
Stox Dude
80,000 done ;-)
Buy 80,000 Limit 0.118 Day Only 11:07 am 09/19/2002 ET ----- -----
Bought 5,000 0.118 11:11 am 09/19/2002 ----- -----
Bought 5,000 0.118 11:11 am 09/19/2002 ----- -----
Bought 10,000 0.118 11:12 am 09/19/2002 ----- -----
Bought 40,000 0.118 11:16 am 09/19/2002 ----- -----
Bought 20,000 0.118 11:17 am 09/19/2002 ----- -----
Status: CLOSED - Filled
Bought 5,000 0.118 11:11 am 09/19/2002 ----- -----
Bought 5,000 0.118 11:11 am 09/19/2002 ----- -----
Bought 10,000 0.118 11:12 am 09/19/2002 ----- -----
Bought 40,000 0.118 11:16 am 09/19/2002 ----- -----
Bought 20,000 0.118 11:17 am 09/19/2002 ----- -----
Status: CLOSED - Filled
19.09.02 17:20
#93
grenke
Stimmt die Amis lieben solche Papiere
und wenn die das ding hochschaukeln, dann gehts ganz ganz schnell über 1€.
gruß grenke
gruß grenke
19.09.02 17:20
#94
Stox Dude
210K shares sollte fuer den zock reichen
jetzt lehnen wir uns zurueck und hoffen auf ein big smile
19.09.02 17:24
#96
kalle4712
mmmhhh- könnte zumindest einen Zock wert sein
Aber heute sind sie ja schon gut gelaufen - meist gibt's dann noch nen Rücksetzer = Abstauberlimit.
Schätze, ich werde mal mitmachen.
Schätze, ich werde mal mitmachen.
19.09.02 17:24
#97
grenke
Calypto Verhandlung mit der Chinesichen Regierung
wenn das da auch klappt,
ich denke dann können wir uns Warm ( Ralph Laurent) anziehen.
gruß Grenke
ich denke dann können wir uns Warm ( Ralph Laurent) anziehen.
gruß Grenke
19.09.02 17:28
#99
Stox Dude
SEC Filings vom 17-09-2002
CALYPTE BIOMEDICAL CORPORATION
2,282,434 SHARES OF COMMON STOCK
You should read this prospectus supplement and the related prospectus
carefully before you invest. Both documents contain information you should
consider when making your investment decision.
On September 4, 2002, we issued a draw down notice to Townsbury
Investments Limited ("TIL") in connection with the common stock purchase
agreement dated August 23, 2001 evidencing a standby equity-based credit
facility between us and TIL. This notice required that TIL purchase up to
$250,000 of our common stock pursuant to a pricing formula in the stock purchase
agreement. The settlement period began on September 5, 2002, ended on September
11, 2002, and settled on September 17, 2002. At the final settlement date on
September 17, 2002, TIL purchased a total of 2,282,434 shares of our common
stock at an average purchase price of $0.110 per share, resulting in proceeds of
$237,000 net of brokerage fees. Ladenburg Thalmann & Co. received $12,500 in
brokerage fees and the escrow agent received $500 in escrow fees in connection
with this drawdown.
The attached prospectus relates to the resale of shares acquired by TIL
pursuant to the stock purchase agreement. Because TIL may sell some or all of
these shares, and because there are currently no agreements, arrangements or
understandings with respect to the sale of any of these shares, we cannot
estimate the actual amount of shares that they will hold after the completion of
the offering.
We will not receive any of the proceeds from this sale of shares by
TIL. However, we did receive the sale price of common stock sold to TIL. We
expect to use the proceeds of this sale of common stock for general corporate
purposes.
This Prospectus Supplement is incorporated by reference into the
Prospectus, and all terms used herein shall have the meaning assigned to them in
the Prospectus. See "Risk Factors" beginning on page 4 of the accompanying
prospectus and on page 37 of our annual report on Form 10-K/A for the year ended
December 31, 2001, which is being delivered to you with the accompanying
prospectus, for a description of certain factors that should be considered by
prospective Investors.
These securities have not been approved or disapproved by the
Securities and Exchange Commission or any state securities commission nor has
the Securities and Exchange Commission or any state securities commission passed
upon the accuracy or adequacy of this prospectus. Any representation to the
contrary is a criminal offense.
The date of this Prospectus Supplement is September 17, 2002.
2,282,434 SHARES OF COMMON STOCK
You should read this prospectus supplement and the related prospectus
carefully before you invest. Both documents contain information you should
consider when making your investment decision.
On September 4, 2002, we issued a draw down notice to Townsbury
Investments Limited ("TIL") in connection with the common stock purchase
agreement dated August 23, 2001 evidencing a standby equity-based credit
facility between us and TIL. This notice required that TIL purchase up to
$250,000 of our common stock pursuant to a pricing formula in the stock purchase
agreement. The settlement period began on September 5, 2002, ended on September
11, 2002, and settled on September 17, 2002. At the final settlement date on
September 17, 2002, TIL purchased a total of 2,282,434 shares of our common
stock at an average purchase price of $0.110 per share, resulting in proceeds of
$237,000 net of brokerage fees. Ladenburg Thalmann & Co. received $12,500 in
brokerage fees and the escrow agent received $500 in escrow fees in connection
with this drawdown.
The attached prospectus relates to the resale of shares acquired by TIL
pursuant to the stock purchase agreement. Because TIL may sell some or all of
these shares, and because there are currently no agreements, arrangements or
understandings with respect to the sale of any of these shares, we cannot
estimate the actual amount of shares that they will hold after the completion of
the offering.
We will not receive any of the proceeds from this sale of shares by
TIL. However, we did receive the sale price of common stock sold to TIL. We
expect to use the proceeds of this sale of common stock for general corporate
purposes.
This Prospectus Supplement is incorporated by reference into the
Prospectus, and all terms used herein shall have the meaning assigned to them in
the Prospectus. See "Risk Factors" beginning on page 4 of the accompanying
prospectus and on page 37 of our annual report on Form 10-K/A for the year ended
December 31, 2001, which is being delivered to you with the accompanying
prospectus, for a description of certain factors that should be considered by
prospective Investors.
These securities have not been approved or disapproved by the
Securities and Exchange Commission or any state securities commission nor has
the Securities and Exchange Commission or any state securities commission passed
upon the accuracy or adequacy of this prospectus. Any representation to the
contrary is a criminal offense.
The date of this Prospectus Supplement is September 17, 2002.

